Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy

Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy:

Abstract

Background/Aim

First-line bevacizumab-based therapies have been shown to improve clinical outcomes in patients with non-squamous non-small-cell lung cancer (NSCLC). We aimed to descriptively analyse patients with non-squamous NSCLC who received a long-term period of maintenance bevacizumab.

Patients and methods

This retrospective study included 104 patients who had already reached a progression-free survival (PFS) of at least 9 months.

Results

Median overall survival and PFS were 30.7 and 15.1 months, respectively. The overall response rate was 83 %. Weight loss ≤5 %, ECOG PS = 0, or low number of metastatic sites seem to be predictive factors of good evolution. The incidence of bevacizumab-related adverse events appeared to be similar as the previous studies.

Conclusion

Our findings show that there is a long-term survivor group whom the administration of bevacizumab resulted in a relevant prolongation of response without new safety signals. Due to the population heterogeneity, it was not possible to identify the standardised predictive factors.

from Cancer via ola Kala on Inoreader
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/29h9GnJ
via IFTTT